Impact of Cachexia on Chemotherapy Efficacy and Survival in Pancreatic Cancer: A Systematic Review and Meta-Analysis

被引:0
作者
Khalil, Muhammad Ashraf [1 ]
Jafri, Syed Ahsan Ali [2 ]
Naqvi, Midhat E. Zahra [2 ]
Jauhar, Iman [2 ]
Kumar, Vijay [2 ]
Ali, Syed Muhammad Sinaan [2 ]
Khalil, Sara [2 ]
Raheem, Abdul [3 ]
Kumar, Ritesh [2 ]
Haseeb, Abdul [1 ]
Shafique, Muhammad Ashir [1 ]
机构
[1] Jinnah Sindh Med Univ, Dept Med, Iqbal Shaheed Rd, Karachi 75510, Pakistan
[2] Liaquat Natl Hosp & Med Coll, Dept Med, Karachi, Pakistan
[3] Baqai Med Univ, Dept Med, Karachi, Pakistan
关键词
pancreatic cancer; cachexia; chemotherapy; overall survival; treatment failure; meta-analysis; prognosis; observational studies; mortality; East Asian populations; DISTRESS;
D O I
10.1177/10732748241292784
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and ObjectivePancreatic cancer (PC) is a significant cause of cancer-related mortality, with limited curative options and high rates of cachexia, a debilitating syndrome associated with poor prognosis. While previous research has linked sarcopenia to poor outcomes in PC, the correlation between cachexia and treatment outcomes remains underexplored. This meta-analysis aims to investigate the association between cachexia and overall survival and time to treatment failure in advanced PC patients undergoing first-line chemotherapy.MethodA systematic search of electronic databases was conducted following PRISMA guidelines. Eligible studies compared cachexic and non-cachexic PC patients, reporting outcomes of observed survival or time to treatment failure. Data extraction and analysis were performed using Comprehensive Meta-Analysis Version 3.3, employing random-effects models and sensitivity analyses to assess heterogeneity and bias.ResultsSeven observational studies involving 2834 PC patients were included. The incidence of cachexia was 45% (95% CI: 0.27-0.65), with a higher prevalence in East Asian populations. Cachexic patients experienced significantly earlier treatment failure (SDM: -2.22, 95% CI: -2.6 to -1.7, P = 0.0001) and higher mortality risk (HR: 2.02, 95% CI: 1.17-3.48, P = 0.011) compared to non-cachexic patients. Overall survival was lower in cachexic patients (SDM: -2.34, 95% CI: -3.7 to -0.90, P = 0.001), with considerable heterogeneity across studies. Meta-regression analysis revealed significant differences between countries but insignificant correlations with age.ConclusionCachexia is associated with reduced overall survival, early chemotherapy failure, and elevated mortality in advanced PC patients undergoing first-line chemotherapy. Recognition and management of cachexia are crucial for optimizing treatment outcomes and improving patient survival. Future research should focus on prospective studies to better understand the impact of cachexia on treatment response and develop tailored interventions to mitigate its adverse effects. Pancreatic cancer (PC) presents a formidable challenge due to its limited treatment options and association with cachexia, a debilitating condition linked to poor prognosis. This meta-analysis investigates the relationship between cachexia and treatment outcomes in advanced PC patients undergoing first-line chemotherapy. Seven observational studies encompassing 2834 patients were analyzed, revealing a 45% incidence of cachexia, notably higher in East Asian populations. Cachexic patients exhibited earlier treatment failure and higher mortality risk compared to non-cachexic counterparts. Their overall survival was significantly reduced, although with notable heterogeneity across studies. Meta-regression analysis highlighted variations between countries but found no significant correlation with age. The findings underscore the importance of recognizing and addressing cachexia to optimize treatment outcomes and enhance patient survival. Future research should emphasize prospective studies to further elucidate cachexia's impact on treatment response and develop tailored interventions to alleviate its adverse effects.
引用
收藏
页数:12
相关论文
共 40 条
  • [31] Understanding cachexia as a cancer metabolism syndrome
    Porporato, P. E.
    [J]. ONCOGENESIS, 2016, 5 : e200 - e200
  • [32] Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
    Rahib, Lola
    Smith, Benjamin D.
    Aizenberg, Rhonda
    Rosenzweig, Allison B.
    Fleshman, Julie M.
    Matrisian, Lynn M.
    [J]. CANCER RESEARCH, 2014, 74 (11) : 2913 - 2921
  • [33] Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice
    Ryan, Aoife M.
    Sullivan, Erin S.
    [J]. PROCEEDINGS OF THE NUTRITION SOCIETY, 2021, 80 (01) : 73 - 91
  • [34] Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis
    Schlick, Konstantin
    Gantschnigg, Antonia
    Seymer, Alexander
    Huemer, Florian
    Greil, Richard
    Weiss, Lukas
    [J]. CANCER MEDICINE, 2023, 12 (16): : 16997 - 17004
  • [35] Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions
    Siddiqui, Jawed A.
    Pothuraju, Ramesh
    Jain, Maneesh
    Batra, Surinder K.
    Nasser, Mohd W.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (02):
  • [36] Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study
    Suzuki, Yukari
    Saito, Kei
    Nakai, Yousuke
    Oyama, Hiroki
    Kanai, Sachiko
    Suzuki, Tatsunori
    Sato, Tatsuya
    Hakuta, Ryunosuke
    Ishigaki, Kazunaga
    Saito, Tomotaka
    Hamada, Tsuyoshi
    Takahara, Naminatsu
    Tateishi, Ryosuke
    Fujishiro, Mitsuhiro
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (03)
  • [37] The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy
    Takeda, Tsuyoshi
    Sasaki, Takashi
    Suzumori, Chisaki
    Mie, Takafumi
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1293 - 1303
  • [38] Psycho-oncologic interventions to reduce distress in cancer patients: a meta-analysis of controlled clinical studies published in People's Republic of China
    Tao, Wei-Wei
    Jiang, Ping
    Liu, Ying
    Aungsuroch, Yupin
    Tao, Xiao-Mei
    [J]. PSYCHO-ONCOLOGY, 2015, 24 (03) : 269 - 278
  • [39] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
    Von Hoff, Daniel D.
    Ervin, Thomas
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey
    Moore, Malcolm
    Seay, Thomas
    Tjulandin, Sergei A.
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Dowden, Scot
    Laheru, Daniel
    Bahary, Nathan
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Goldstein, David
    Van Cutsem, Eric
    Wei, Xinyu
    Iglesias, Jose
    Renschler, Markus F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18) : 1691 - 1703
  • [40] Wong HCY, 2019, NUTR CANCER, V71, P954, DOI [10.1080/01635581.2019.1595047, 10.1080/01635581.20]